Revolutionizing Lipid Management The fight against cardiovascular disease is taking a significant step forward as Ribo Biotherapeutics recently announced the submission of a clinical trial application in Europe for its innovative drug candidate, SR122. This move marks a major milestone in the company’s mission to address the complex challenges of mixed and severe dyslipidemia. Understanding…